PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...
A novel bioengineering strategy utilizing peptide display technology on the AAV1 capsid has successfully generated ...
PHILADELPHIA, PA — Latus Bio, Inc. has unveiled groundbreaking research on a novel adeno-associated virus (AAV) capsid variant, AAV-Ep+, which shows significant promise for advancing gene therapy ...
Adeno-associated virus (AAV) preparations remain highly heterogeneous through upstream and downstream bioprocessing phases. Characterizing empty, partial, full, overfilled capsids and encapsulated ...
Viral vectors, such as adeno-associated viruses (AAV) and lentiviral viruses (LVV), are recently at the forefront of biotherapeutic development for the support of cell and gene therapies. As with ...
- AAV-SLB101 is the capsid used in SGT-003, Solid’s next-generation Duchenne gene therapy, expected to enter the clinic in late-2023 - - Additional novel capsids based on AAV-SLB101 binding protein ...
"CMRI has pioneered the work of establishing barcoded AAV capsid kits, which allow for NGS-based parallel evaluation of large numbers of AAVs for their performance at both DNA (proxy for cell entry) ...
Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...
Solid Biosciences signed a gene therapy agreement with CDMO Andelyn Biosciences for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101. Solid grants Andelyn a non-exclusive worldwide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results